Nascent Biotech and Hisun Announce an Exclusive License Agreement for the Development and Commercialization of Nascent’s Primary Asset, Pritumumab, in Mainland China
Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China. July 18, 2016 10:00 am EDT Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, [...]